TAK Form 144: $414K Insider Sale Represents Just 0.02% of Shares

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited (TAK) – Form 144 filing discloses a planned insider sale of 26,874 American Depositary Shares (ADSs) with an aggregate market value of $414,397.08. The transaction will be executed through Interactive Brokers on the NYSE around 9 July 2025. The seller received the shares as part of restricted stock unit (RSU) awards that vested on 1 July 2025. No prior sales by this individual were reported in the past three months. Relative to the company’s 123.49 million ADSs outstanding, the proposed sale represents roughly 0.02% of shares, suggesting an immaterial dilution impact. The filer certifies no knowledge of undisclosed adverse information. While Form 144 notices can flag insider sentiment, the modest size and routine compensation-related nature of this sale indicate limited market significance.

Positive

• Very small relative size (0.02% of ADSs) limits dilution and market impact
• Sale stems from RSU vesting, indicating routine compensation-related diversification rather than strategic insider exit

Negative

• Insider selling can be perceived negatively for sentiment, even if immaterial in size

Insights

Securities Analyst

TL;DR – Small RSU-driven insider sale; limited impact on TAK shares.

The Form 144 covers 26,874 ADSs, worth just over $414k, equal to ~0.02% of total ADSs outstanding. The stock was acquired via RSU vesting a week earlier, implying a routine liquidity move rather than a strategic off-load. Lack of prior three-month sales and the certification of no undisclosed adverse information reduce red-flag concerns. Given Takeda’s $35 bn+ market cap, this filing is not financially material. Investors may note it as part of broader insider-trading trends, but on a standalone basis it is neutral for valuation and sentiment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/09/2025 - 06:29 AM Learn about SEC filing dates

FAQ

How many Takeda (TAK) shares are being sold under this Form 144?

The filing covers 26,874 ADSs.

What is the market value of the shares listed in the Form 144 for TAK?

The aggregate market value is $414,397.08.

When will the TAK insider sale occur?

The approximate sale date disclosed is 9 July 2025.

How were the Takeda shares acquired prior to the planned sale?

They were obtained through restricted stock unit (RSU) awards that vested on 1 July 2025.

What percentage of Takeda’s outstanding ADSs does the proposed sale represent?

Approximately 0.02% of the 123.49 million ADSs outstanding.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	26874	414397.08	123490548	07/09/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2025	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			62660	07/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)